Genmab — September 2020
-
Det ene behøver ikke at udelukke det andet. GEN kan tabe det hele, vinde det hele - og alt der i mellem
-
...it does seem like somebody had a bit of a kip when the dara deal was written down
-
Agree E L, and if Hexa-CD38 is as good as Jan believes, we don’t have to worry over the effects after 2030
-
Du har en fin pointe Mcjean, men grundlæggende er det svært at se andet end at Genmab burde kunne vinde begge slagsmål. M.h.t. HALO burde der slet ikke være tvivl. Aftalen er indgået for at udvide brugen og øge Jansens salg. Det må de alene betale for, alt andet ville være urimeligt. Perioden burde Gen også vinde. Det vigtige er imidlertid at der kun bliver en tvist fordi de ikke kunne blive enige. Nu er banen kridtet op og - set med Jansen øjne - er Genmab i den grad blevet en opkøbsmulighed. B
-
And if JNJ decides not to exercise the Hexa-cd38 option, Genmab can carry on alone, or with another partner. That would really create some noise...
-
GB When is the cut-off date for the Hexa cd38 option?
-
Yes they can
-
Det ville være en særdeles usædvanlig optakt til et opkøb
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind